Amarin Corporation Plc (AMRN)
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
📉 **NEGATIVE** • Medium confidence analysis (66%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (15%) **Content type:** Clinical